Publikace
- Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite2017 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?2016 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo2015 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury2014 | Farmaceutická fakulta v Hradci Králové
- Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells2013 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium2013 | Farmaceutická fakulta v Hradci Králové
- Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase II beta Interactions2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II beta inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
Loading network view...